secwatch.observer — SEC 8-K summary
======================================

Issuer:     Benitec Biopharma Inc. (BNTC)
CIK:        0001808898
Form:       8-K
Filed at:   2026-05-29T20:10:56+00:00
Accession:  0001193125-26-248289
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Benitec Biopharma appoints David Friedman to board; Megan Boston resigns as director but remains CFO
--------------------------------------------------------------------------------

- David Friedman joined board as Class III director effective May 22, 2026; term until 2028 annual meeting.
- Friedman granted options to purchase 35,000 shares at closing price on May 26, 2026; vesting by next annual meeting or 1 year.
- Megan Boston resigned from board effective May 22, 2026; continues as CFO and secretary; no dispute.
- Friedman entitled to standard non-employee director compensation; will enter indemnification agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808898/000119312526248289/0001193125-26-248289-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808898/000119312526248289/bntc-20260522.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-248289

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer